To confirm these observations, we also performed ELISA assay for TGF-β in tumor lysate of CI66 tumors and observed 60% reduction in TGF-β in atovaquone-treated tumors as compared to control tumors (Figure 4C). The gene discussed is TGFB1; the disease is neoplasm.